Table 3 Between-group comparisons
Outcome | Group | N | T1 (15 Min.) | T2 (90 Min.) | T3 (1 Day) | T4 (2 Day) |
|---|---|---|---|---|---|---|
8OHdG (ng/mL) | MSM | 11 | 10.87 (9.90–11.83) | 10.72 (9.55–11.89) | 9.12 (8.09–10.15) | 9.13 (8.13–10.13) |
Placebo | 11 | 10.32 (9.36–11.29) | 9.79 (8.61–10.96) | 8.08 (7.05–9.11) | 7.86 (6.86–8.86) | |
ΔGroup | 0.54 (−0.84–1.92) | 0.94 (−0.74–2.61) | 1.04 (−0.43–2.51) | 1.27 (−0.17–2.71) | ||
MDA (μM) | MSM | 11 | 26.6 (21.7–31.4) | 18.8 (14.9–22.6) | 15.7 (13.3–18.1) | 15.9 (13.0–18.8) |
Placebo | 11 | 22.9 (18.1–27.7) | 17.9 (14.0–21.7) | 16.7 (14.3–19.2) | 18.7 (15.8–21.6) | |
ΔGroup | 3.7 (−3.2–10.5) | 0.9 (−4.6–6.4) | −1.1 (−4.5–2.4) | −2.8 (−6.9–1.4) | ||
logCK (U/L) | MSM | 11 | 2.26 (2.08–2.43) | 2.33 (2.15–2.52) | 2.67 (2.38–2.95) | 2.40 (2.14–2.66) |
Placebo | 11 | 2.24 (2.07–2.41) | 2.30 (2.12–2.48) | 2.49 (2.21–2.78) | 2.29 (2.03–2.55) | |
ΔGroup | 0.02 (−0.23–0.26) | 0.03 (−0.23–0.29) | 0.18 (−0.24–0.58) | 0.11 (−0.26–0.48) | ||
LDH (U/L) | MSM | 11 | 224.3 (199.2–249.3) | 228.3 (199.3–257.2) | 191.0 (172.2–209.7) | 183.1 (163.4–202.7) |
Placebo | 11 | 236.5 (211.5–261.5) | 236.6 (207.6–265.5) | 185.8 (167.0–204.5) | 177.1 (157.5–196.7) | |
ΔGroup | −12.2 (−47.8–23.4) | −8.3 (−49.5–32.9) | 5.2 (−21.5–31.9) | 6.0 (−22.0–33.9) | ||
Muscle Pain (mm) | MSM | 11 | 28.7 (11.6–45.9) | 28.3 (9.9–46.8) | 31.2 (14.3–48.2) | 21.8 (7.6–35.9) |
Placebo | 10 | 48.5 (32.2–64.9) | 38.9 (21.2–56.5) | 41.2 (25.0–57.3) | 21.1 (7.6–34.6) | |
ΔGroup | −19.8 a (−43.7–4.1) | −10.6 a (−36.3–15.2) | −10.0 a (−33.5–13.7) | −0.7 (−20.4–19.1) | ||
Joint Pain (mm) | MSM | 11 | 29.1 (14.7–43.5) | 26.6 (9.6–43.6) | 18.6 (2.9–34.2) | 14.9 (−2.8–32.5) |
Placebo | 10 | 38.0 (24.2–51.7) | 35.7 (19.5–51.9) | 29.3 (14.4–44.2) | 17.9 (1.1–34.7) | |
ΔGroup | −8.9 (−29.1–11.3) | −9.1 (−33.0–14.7) | −10.7 a (−32.7–11.2) | −3.0 (−27.8–21.7) | ||